Drilldown: Medicines
Use the filters below to narrow your results.
generic:
25B-NBOH (1) ·
25B-NBOMe (1) ·
25C-NBOH (1) ·
25C-NBOMe (1) ·
25I-NBOH (1) ·
25I-NBOMe (1) ·
25N-NBOMe (1) ·
2C-B (1) ·
2C-B-FLY (1) ·
2C-C (1) ·
2C-D (1) ·
2C-E (1) ·
2C-I (1) ·
2C-P (1) ·
2C-T-2 (1) ·
2C-T-7 (1) ·
Allylescaline (1) ·
Bromo-DragonFLY (1) ·
DOB (1) ·
DOC (1) ·
DOI (1) ·
DOM (1) ·
Escaline (1) ·
Methallylescaline (1) ·
Proscaline (1) ·
Rizatriptan (benzoate) (1) ·
Sumatriptan (succinate) (1) ·
Sumatriptan / Naproxen (1) ·
TMA-2 (1)
brand:
None (25) ·
Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) ·
Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) (1) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Treximet (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
'"`UNIQ--vote-000015CE-QINU`"' The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses'"`UNIQ--ref-000015CF-QINU`"'. (1)
uses:
starting dose:
None (26) ·
1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours (1) ·
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours (1) ·
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1)
preparations:
None (26) ·
85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric) (1) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) ·
Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (25) ·
Not well characterized (1) ·
Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' (1) ·
~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) ·
~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"' (1)
pregnancy:
None (25) ·
Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not established (1)
legal:
None (25) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' (1)
Showing below up to 29 results in range #1 to #29.